[7] Common side effects include dizziness, trouble sleeping, increased sweating, constipation, sleepiness, anxiety, and sexual problems.

[5] Serious side effects may include suicide in those under the age of 25, serotonin syndrome, bleeding, mania, and high blood pressure.

[5] There is a high risk of withdrawal syndrome which may occur if the dose is decreased or the medication is completely stopped.

[19] Wyeth announced on 23 January 2007 that it received an approvable letter from the Food and Drug Administration for desvenlafaxine.

[23][24] In 2009, an application to market desvenlafaxine for major depressive disorder in the European Union was declined.

It was listed on the Pharmaceutical Benefits Scheme (PBS) in 2008 for the treatment of major depressive disorders.